Gynecological surveillance and surgery outcomes in dutch lynch syndrome carriers by Eikenboom, E.L. (Ellis L.) et al.
cancers
Article
Gynecological Surveillance and Surgery Outcomes in Dutch
Lynch Syndrome Carriers
Ellis L. Eikenboom 1,2, Helena C. van Doorn 3 , Winand N. M. Dinjens 4, Hendrikus J. Dubbink 4 ,
Willemina R. R. Geurts-Giele 4, Manon C. W. Spaander 2 , Carli M. J. Tops 5, Anja Wagner 1,†
and Anne Goverde 1,*,†


Citation: Eikenboom, E.L.; van
Doorn, H.C.; Dinjens, W.N.M.;
Dubbink, H.J.; Geurts-Giele, W.R.R.;
Spaander, M.C.W.; Tops, C.M.J.;
Wagner, A.; Goverde, A.
Gynecological Surveillance and
Surgery Outcomes in Dutch Lynch
Syndrome Carriers. Cancers 2021, 13,
459. https://doi.org/10.3390/
cancers13030459
Academic Editors: Paola Izzo and
Francesca Duraturo
Received: 30 December 2020
Accepted: 23 January 2021
Published: 26 January 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Clinical Genetics, Erasmus MC Cancer Institute, University Medical Center
Rotterdam, 3000 CA Rotterdam, The Netherlands; e.eikenboom@erasmusmc.nl (E.L.E.);
a.wagner@erasmusmc.nl (A.W.)
2 Department of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, University Medical Center
Rotterdam, 3000 CA Rotterdam, The Netherlands; v.spaander@erasmusmc.nl
3 Department of Gynecology, Erasmus MC Cancer Institute, University Medical Center Rotterdam,
3000 CA Rotterdam, The Netherlands; h.vandoorn@erasmusmc.nl
4 Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam,
3000 CA Rotterdam, The Netherlands; w.dinjens@erasmusmc.nl (W.N.M.D.);
h.dubbink@erasmusmc.nl (H.J.D.); w.geurts-giele@erasmusmc.nl (W.R.R.G.-G.)
5 Department of Clinical Genetics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands;
C.M.Tops@lumc.nl
* Correspondence: a.goverde.1@erasmusmc.nl
† These authors contributed equally to this paper.
Simple Summary: Female Lynch syndrome (LS) carriers have an increased risk to develop endome-
trial and ovarian cancer. In the Netherlands, carriers are therefore advised annual gynecological
surveillance and eventually, risk-reducing surgery. Global gynecological LS surveillance guide-
lines are scarce and based on limited evidence. These are, however, warranted to offer accurate
surveillance. To provide more insight into surveillance outcomes, this study assessed outcomes of
gynecological surveillance and risk-reducing surgery in 164 LS carriers diagnosed in our center, with
a median follow-up of 5.6 years per carrier. Although most surveillance visits happened within
an advised timeframe, we observed large variability in how gynecological surveillance visits were
performed. This finding stresses the need for development of clear and evidence-based guidelines.
Endometrial cancers identified at surveillance were all found in early stage, mostly symptomatic,
questioning surveillance benefit. Large, prospective studies should assess to what extent current LS
surveillance programs contribute to early detection of gynecological tumors.
Abstract: Lynch syndrome (LS) is caused by pathogenic germline variants in DNA mismatch repair
(MMR) genes, predisposing female carriers for endometrial cancer (EC) and ovarian cancer (OC).
Since gynecological LS surveillance guidelines are based on little evidence, we assessed its outcomes.
Data regarding gynecological tumors, surveillance, and (risk-reducing) surgery were collected from
female LS carriers diagnosed in our center since 1993. Of 505 female carriers, 104 had a gynecological
malignancy prior to genetic LS diagnosis. Of 264 carriers eligible for gynecological management,
164 carriers gave informed consent and had available surveillance data: 38 MLH1, 25 MSH2, 82 MSH6,
and 19 PMS2 carriers (median follow-up 5.6 years). Surveillance intervals were within advised time
in >80%. Transvaginal ultrasound, endometrial sampling, and CA125 measurements were performed
in 76.8%, 35.9%, and 40.6%, respectively. Four symptomatic ECs, one symptomatic OC, and one
asymptomatic EC were diagnosed. Endometrial hyperplasia was found in eight carriers, of whom three
were symptomatic. Risk-reducing surgery was performed in 73 (45.5%) carriers (median age 51 years),
revealing two asymptomatic ECs. All ECs were diagnosed in FIGO I. Gynecological management in LS
carriers varied largely, stressing the need for uniform, evidence-based guidelines. Most ECs presented
early and symptomatically, questioning the surveillance benefit in its current form.
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1. Introduction
Lynch syndrome (LS) is one of the most prevalent hereditary cancer predisposition
syndromes [1]. LS is caused by germline mutations in DNA mismatch repair (MMR) genes
MLH1, MSH2, MSH6, PMS2, or by a deletion of the 3′ end of the EpCAM (TACSTD1)
gene. Pathogenic germline variants in MMR genes, causative for LS, were first discovered
in the 1990s, with MSH2 being first (1993), followed by MLH1 (1994) and PMS2 (1994),
MSH6 (1997), and EpCAM (2009) [2–6]. Besides an increased risk of up to 57.1% to develop
colorectal cancer (CRC), female carriers are also at high risk to develop gynecological
malignancies, such as endometrial cancer (EC) and cancer in the ovaries (OC) [7–9]. A recent
study showed that the risks for EC development by age 75 are 37%, 48%, 41%, and 12%
for MLH1, MSH2, MSH6, and PMS2 carriers, respectively. The risk of developing OC by
age 75 was found to be between 3% and 17%, depending on MMR gene involved [10].
Besides CRC, EC, and OC, LS carriers are also at an increased risk to develop other types
of tumors, such as tumors of the small intestine, brain, and skin. Although LS carriers have
an increased risk, compared to the general population, to develop these tumors, these risks
are lower than for CRC, EC, and OC development [11].
Development of surveillance strategies, such as biennial colonoscopy, led to a decrease
in CRC-related death [12–14]. Female LS carriers are globally also advised a regular gy-
necological examination [15,16]. Exact guidelines differ per country, but usually include
at least annual or biennial gynecological examination with transvaginal ultrasound to
assess the endometrium and ovaries in women 25–40 years to 60 years [17–21]. Uniform
guidelines for gynecological surveillance are not yet available: on the one hand, little is
known about premalignant stages of LS-associated gynecological tumors. On the other
hand, it is hitherto not clear to what extent screening can contribute to the detection of
gynecological tumors in early stages [15,21–24]. In the Netherlands, guidelines regarding
gynecological management in LS carriers were revised in December 2015. Before this time,
LS carriers could opt for annual to biennial gynecological assessment, from the age of 30 to
35 years. From 2016 onwards, female LS carriers are advised to have an annual transvaginal
ultrasound, endometrial sampling, and assessment of the ovaries by ultrasound and/or
CA125 measurements between age 40 and 60 years [19]. The age 40–60 years is based on
the assumption that EC symptoms, such as post-menopausal bleeding, could potentially be
misinterpreted as perimenopausal bleeding. In case carriers have a relative with a gyneco-
logical tumor identified before the age of 40 years, carriers are advised to start surveillance
five years before this age. From the initiation of gynecological surveillance programs,
carriers have been extensively informed about (early) symptoms of a gynecological tumor,
regardless of their age, as the majority of ECs presents with gynecological complaints, such
as irregular bleeding [25]. Possibilities of risk-reducing surgery are also being continuously
discussed, such as a total hysterectomy and/or bilateral salpingo-oophorectomy after com-
pleted childbearing, to further decrease the risk of gynecological cancer development [26].
Nevertheless, little is known about the yield of gynecological surveillance in LS carriers.
Additionally, the outcomes of the Dutch gynecological surveillance strategy have never
been assessed so far. However, understanding these outcomes may be useful for the de-
velopment of tailored gynecological management strategies for these carriers. Therefore,
the results of gynecological management in female LS carriers diagnosed at our center
were assessed.
2. Materials and Methods
For this retrospective cohort study, we assessed prevalence of gynecological tumors,
outcomes of surveillance and the yield of risk-reducing surgery in female carriers of a
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pathogenic variant in one of the MMR genes, from here on referred to as female LS carriers,
diagnosed in our center. Outcomes were assessed for the different MMR gene carrier groups.
As EpCAM carriers were previously found to have a significantly different risk to develop
EC compared to MSH2 carriers [27], these carriers were excluded from further analyses.
We did not include carriers with biallelic pathogenic MMR germline variants (congenital
mismatch repair deficiency) or LS carriers with pathogenic variants in more than one MMR
gene. Gynecological surveillance was not applicable in case of post-mortem LS diagnosis,
in carriers having had gynecological surgery prior to LS diagnosis or in case carriers were
aged younger or older than the advised age for surveillance. From cases with gynecological
surgery due to EC or OC, age at diagnosis and the 2009 Fédération Internationale de
Gynécologie et d’Obstétrique (FIGO) stage for the classification of gynecological tumors [28]
were assessed.
2.1. Patient Selection and Data Extraction
The department of Clinical Genetics of the Erasmus MC, University Medical Center in
Rotterdam, serves as a regional referral center for the south-west of the Netherlands. Upon
LS diagnosis, a genetic counselor informs LS carriers about the gynecological tumor risk
and the possibilities of surveillance and/or surgery to reduce these risks. LS carriers who
are (nearly) eligible for gynecological surveillance or surgery are referred to the department
of gynecology. Carriers referred to the department of gynecology in our center receive a
brochure summarizing these features.
From our database, we selected all female LS carriers diagnosed between 1993 and
2020. Subsequently, female LS carriers eligible for gynecological surveillance and/or
risk-reducing surgery were asked for informed consent to retrieve and analyze their data
regarding gynecological surveillance and surgery. Data were retrieved from the hospital
charts where surveillance or surgery had been performed. Data on surveillance visits
included the number of surveillance visits, interval between two subsequent visits, out-
come of transvaginal ultrasound, endometrial sampling, and Cancer Antigen 125 (CA125)
measurements. CA125 is a tumor marker, and may be elevated in the blood of patients
with OC and EC [29]. Data on risk-reducing surgery included type and date of surgery,
pathology, and development of gynecological tumors. Data were retrieved up to Octo-
ber 2020. In case patient charts did not mention any information whatsoever regarding
transvaginal ultrasound, CA125 measurements, or endometrial sampling, we assumed
the corresponding assay was not performed. If the endometrial thickness was >10 mm
in premenopausal women during the proliferative phase or >4 mm in postmenopausal
women, or if the medical report mentioned a “thickened” endometrium, we concluded that
the endometrial thickness was abnormal. CA125 values were considered to be elevated
when >35 kU/L. All surveillance visits before risk-reducing surgery were included in
our study. Permission of the Erasmus Medical Center Committee on Research Involving
Human Subjects was granted (MEC-2020-0600).
2.2. Statistical Analyses
Data were analyzed in SPSS statistical software version 25.0. Differences in baseline
characteristics were assessed by a χ2 test (or Fisher’s exact test in the case of paucity
of data) or Kruskal–Wallis test, for categorical and quantitative variables, respectively.
p-values < 0.05 were considered statistically significant.
3. Results
3.1. Patient Characteristics
Since 1993, we diagnosed a pathogenic MMR germline variant in 505 females (MLH1
n = 107, MSH2 n = 90, MSH6 n = 224, and PMS2 n = 84). In 241 carriers, gynecological
surveillance and surgery was not applicable (Figure 1). In 104 of these 241 carriers, the
indication for surgery had been a gynecological malignancy (EC n = 85, OC n = 17, and
gynecological organ of origin not specified n = 2). Forty-one ECs (80.4%) were found in
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FIGO stage I, three in FIGO stage II (5.9%), three in FIGO stage III (5.9%), four in FIGO
stage IV (7.8%), and unknown in 34 ECs. The majority of the ECs were identified in age
category 40–60 years (n = 60, 71.4%); two ECs in patients younger than 40 years (2.4%),
21 in patients older than 60 years (25.0%), and for one patient, age at EC diagnosis was
unknown. Ten OCs (58.8%) were found in FIGO stage I, two in FIGO stage II (11.8%),
three in FIGO stage III (17.6%), one in FIGO stage IV (5.9%), and unknown in one. The
majority of the OCs were diagnosed in age category 40–60 years (n = 9, 52.9%); four OCs
were diagnosed in patients younger than 40 years of age (23.5%), three in patients older
than 60 years of age (17.6%), and for one patient, age at OC diagnosis was unknown.
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Figure 1. Overview of female Lynch syndrome (LS) carriers.
Of the 264 carriers eligible for gynecological surveillance and/or risk-reducing surgery,
gynecological management data were available for 164. Data were not available because
carriers died before the time of asking informed consent, because they did not grant
informed consent to retrieve their medical data, or because carriers had not been enrolled
in a gynecological surveillance program. Of the 164 carriers with gynecological surveillance
data, 38 (23.2%) carried a pathogenic germline variant in MLH1, 25 (15.2%) in MSH2, 82
(50.0%) in MSH6, and 19 (11.6%) in PMS2 (Table 1). The mean ages at first gynecological
surveillance visit before 2016 and from 2016 onwards were 46.0 years (interquartile range
(IQR) 37.9–53.6 years) and 53.8 years (IQR 42.4–61.1), respectively, and did not differ
significantly between MLH1, MSH2, MSH6, and PMS2 carrier groups. As expected due to
adjustment of the Dutch LS gynecological surveillance guidelines in December 2015, LS
carriers were overall significantly older at the first surveillance visit from 2016 onwards
(p = 0.007).
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Table 1. Characteristics of carriers with gynecological surveillance.
Characteristics Total MLH1 MSH2 MSH6 PMS2 p-Value
All patients, N 164 38 25 82 19
Of which diagnosed
before 2016 139 33 23 70 13
Of which diagnosed since 2016 25 5 2 12 6
Age at first visit, before 2016,
median (IQR, range)
46.0 yr (IQR 37.9–53.6,
range 21.5–75.0)
44.5 yr (IQR 36.2–52.2,
range 21.5–65.2)
43.4 yr (IQR 34.7–50.8,
range 26.8–54.6)
48.2 yr (IQR 39.2–55.6,
range 28.6–75.0)
49.2 yr (IQR 34.9–56.5,
range 26.3–70.9) 0.143
Age at first visit since 2016,
median (IQR, range)
53.8 yr (IQR 42.4–61.1,
range 30.0–71.3)
48.3 yr (IQR 37.1–51.1,
range 30.0–61.1)
57.4 yr (IQR 54.7–60.2,
range 54.7–60.2)
47.6 yr (IQR 42.3–63.0,
range 38.5–71.3)
58.4 yr (IQR 56.5–64.7,
range 53.7–65.3) 0.175
Follow-up years 685.4 yr 237.7 yr 146.2 yr 238.3 yr 63.2 yr












Number of visits ∆,
median N (IQR)
3 (IQR 2–6) 4 (IQR 2–8) 3 (IQR 2–6) 3 (IQR 1–5) 3 (IQR 1–5) <0.001
Visits with tests performed, N
(% of total visits)
Transvaginal
ultrasound 522 (76.8%) 184 (79.0%) 79 (72.5%) 207 (77.8%) 52 (72.2%) 0.431
Ca125 276 (40.6%) 128 (54.9%) 18 (16.5%) 117 (44.0%) 13 (18.1%) <0.001
Endometrial sampling 244 (35.9%) 68 (29.2%) 34 (31.2%) 99 (37.2%) 43 (59.7%) <0.001
∆ Including first surveillance visit; Yr = years, visits = surveillance visits
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3.2. Surveillance
3.2.1. Characteristics of Surveillance
On average, the 164 LS carriers under surveillance had 3 (IQR 2–6) surveillance visits,
corresponding with a median of 5.6 follow-up years (IQR 3.0–9.0 years) per carrier. Median
number of follow-up years was significantly higher for MLH1/MSH2 carriers than for
MSH6/PMS2 carriers (p = 0.009, Table 1).
Transvaginal ultrasounds, endometrial sampling, and CA125 measurements were
performed in 76.8%, 35.9%, and 40.6% of all surveillance visits, respectively. In 60.8% of
carriers, at least one CA125 measurement was performed. In gynecological surveillance
visits of MLH1 and MSH6 carriers, CA125 measurements were significantly more often
performed, compared to those of MSH2 and PMS2 carriers (54.9% and 44.0%, vs. 16.5%
and 18.1%, respectively; p < 0.001). Endometrial sampling was significantly more often
performed in PMS2 carriers (p < 0.001). In all LS carriers under 50 years of age, endometrial
sampling was significantly more often performed compared to carriers over 50 years of
age (p = 0.024).
3.2.2. First Surveillance Visit
In 57 of 164 carriers (34.8%) data of only one surveillance visit were available (Figure 1,
Table 2). Of all carriers, MSH6 carriers had significantly more often just one surveillance
visit (p = 0.040). Reasons for cessation of the follow-up varied, with the majority of
carriers (n = 30) having subsequent risk-reducing surgery. Upon the first surveillance visit,
one EC was identified in a 64-year old MSH6 carrier, without gynecological complaints
(Tables 2 and 3). Ten of the 164 carriers (6.1%) had another abnormality identified upon
the first surveillance visit: an increased CA125 value (n = 2), a thickened endometrium
(n = 4), and endometrial hyperplasia (n = 5). All the latter carriers opted for subsequent
risk-reducing surgery; pathological assessment did not show the presence of an EC in four,
a pathology report was not available in one.
3.2.3. Second or Higher Surveillance Visit
For 107 carriers, the data of subsequent surveillance visits were available. The median
interval between subsequent surveillance visits was 1.0 years (before 2016 IQR 0.9–1.4 years,
from 2016 onwards IQR 1.0–1.2, Table 2). Before 2016, MSH2 and PMS2 carriers had
a significantly longer interval between subsequent surveillance visits (1.1 years, IQR
1.0–2.0 for MSH2, IQR 1.0–1.4 for PMS2, p < 0.001). The median interval in these carriers
decreased from 2016 onwards, having no significant difference between carrier groups
(p = 0.277). In carriers enrolled in surveillance before 2016, who were advised to have
gynecological surveillance every 1–2 years, a median of 82.3% of subsequent surveillance
visits was performed within 24 months. Carriers with surveillance visits from 2016 onwards
were advised annual gynecological surveillance: here, a median of 83.3% of subsequent
surveillance visits was performed within 15 months.
After the first surveillance visit, five ECs were identified (two MLH1 carriers, two
MSH2, and one MSH6; Tables 2 and 3); all were found in FIGO stage I. One of these
ECs was found by endometrial biopsy in carriers without gynecological complaints, the
remaining four were found in carriers with gynecological complaints. Upon pathological
assessment after risk-reducing surgery, another ECs was found in a 58-year old MSH6
carrier (Tables 3 and 4). In five of these six carriers with EC, the tumor was identified at age
40–60 years (Table 3). Of note, in only two patients diagnosed with EC during surveillance,
both transvaginal ultrasound and endometrial sampling were performed at the previous
gynecological surveillance visit and these assays did not show clues for a premalignancy.
One FIGO stage IV OC was diagnosed in a 48-year old MSH2 carrier, who was presented
with blood loss. At her previous visit less than one year earlier, the transvaginal ultrasound
was unremarkable (Tables 2 and 3).
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Table 2. Characteristics of gynecological surveillance visits.
Characteristics Total MLH1 MSH2 MSH6 PMS2 p-Value
All patients, N 164 38 25 82 19
Patients with only one
surveillance visit, N 57 8 7 37 5 0.040
Surgery after first visit,
including for tumor 30 3 2 21
‡ 4
Recent primary visit
(<2 years) 5 0 0 3 1
Aged >60 years
(since 2016) 2 1 0 1 0
Reason unknown 20 4 5 12 0
Abnormalities at first
surveillance visit, N **
Ca125 > 35 kU/L 2 1 0 1 0
Thickened
Endometrium * 5 2 0 3 0
Hyperplasia 5 0 0 4 1
EC 1 0 0 1 ‡ 0
Patients with ≥2 surveillance visits, N (expected count ∆) 107 (127) 30 (34) 18 (23) 45 (57) 14 (14)
Interval between visits
before 2016, median (IQR) 1.0 (IQR 0.9–1.5) 1.0 (IQR 0.8–1.3) 1.1 (IQR 1.0–2.0) 1.0 (IQR 0.6–1.4) 1.1 (IQR 1.0–1.4) 0.001
Interval between visits
since 2016, median (IQR) 1.0 (IQR 1.0–1.2) 1.0 (IQR 1.0–1.3) 1.1 (IQR 1.0–1.2) 1.0 (IQR 0.8–1.1) 1.0 (IQR 1.0–1.1) 0.277
Subsequent surveillance visit <24 months before 2016,
N of total (%) 343/417 (82.3%) 131/155 (84.5%) 47/64 (73.43%) 139/167 (83.2%) 26/31 (83.9%) 0.249
Subsequent surveillance visit <15 months/all visits since
2016, N of total (%) 80/96 (83.3%) 26/37 (72.2%) 11/14 (78.6%) 24/26 (92.3%) 18/19 (94.7%) 0.091
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Table 2. Cont.
Characteristics Total MLH1 MSH2 MSH6 PMS2 p-Value
Abnormalities at ≥2 surveillance visit, N (% of carriers
with ≥2 surveillance visits) **
Ca125 > 35 kU/L 8 (7.5%) 2 (6.7%) 1 (5.6%) 2 (4.4%) 1 (7.1%)
Thickened
Endometrium * 10 (9.3%) 0 2 (11.1%) 6 (13.3%) 2 (14.3%)
Hyperplasia 3 1 1 1 0
Tumor 6 2 3 1 0
EC 5 2 2 1 0
OC 1 0 1 0 0
* If endometrial thickness was >10 mm in premenopausal women (during proliferative phase) or >4 mm in postmenopausal women, it was considered to be thickened. ** Carriers with abnormalities identified
upon more than one visit were only counted once (only the first visit with an abnormal outcome). ‡ One endometrial cancer (EC) was identified in an MSH6 carrier, with subsequent surgery (more information in
Table 4). ∆ Expected count was based on the identified number of patients with two or more surveillance visits summed with the number of patients with unknown cause for cessation of follow-up.
Table 3. Gynecological hyperplasia and malignancies identified during surveillance.




Surveillance Visits Prior to









Endometrial hyperplasia MSH6 51 N.A. N.A. N.A. Unknown
Endometrial hyperplasia PMS2 49 N.A. N.A. N.A. Irregular cycle
Endometrial hyperplasia MSH6 52 5 N.A. N.A.
Hypermenorrhea, hyperplasia identified
upon pathological
examination after risk-reducing surgery,
preoperative endometrial sampling could
not rule out hyperplasia
Endometrial hyperplasia MSH2 38 4 1.0
Transvaginal ultrasound,




Endometrial hyperplasia MLH1 48 3 1.1 Transvaginalultrasound No complaints
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Table 3. Cont.




Surveillance Visits Prior to










(FIGO IA grade 1) MSH6 64 N.A. N.A. N.A.
No complaints
Endometrial hyperplasia MSH6 46 N.A. N.A. N.A. Hypermenorrhea
Endometrial hyperplasia MSH6 46 N.A. N.A. N.A. Unknown
Endometrial hyperplasia MSH6 57 N.A. N.A. N.A. Unknown
EC
(FIGO IB, grade 1) MSH6 58 1 N.A. N.A.
No complaints, EC identified upon
pathological









No complaints, no anomalies at ultrasound,
but endometrial sampling suggestive of
pre-malignancy.
EC
(FIGO I) MLH1 52 1 0.5
Transvaginal
ultrasound Complaints: irregular blood loss
EC






(FIGO IV) MSH2 48 1 1.0
Transvaginal
ultrasound
unknown, no Ca125 or
endometrial sampling
Complaints:
intermenstrual blood loss, menorrhagia.
EC




blood loss after miscarriage
EC
(FIGO IA grade 2) MSH6 59 3 0.1
Transvaginal ultrasound,
Ca125 (outcome unknown), no
endometrial sampling
Complaints:
postmenopausal blood loss since last visit
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Table 4. Gynecological surgery in patients at gynecological surveillance.
Characteristics Total MLH1 MSH2 MSH6 PMS2 p-Value
Gynecological surgery ‡,
N (% of total carriers)
73 (45.5%) 14 (36.8%) 7 (32.0%) 44 (53.7%) 8 (42.1%) 0.015
Of which performed before 2016 54 7 6 35 6 0.004
Of which performed since 2016 19 7 1 9 2 1.00
Type of surgery
Hysterectomy 11 3 3 5 0
Ovariectomy ∆ 4 1 2 1 0
Hysterectomy with bilateral salpingo
oophorectomy 58 10 2 38 8
Age at surgery before 2016,
median (IQR, range)
51 years
(IQR 45–54, range 20–72)
52 years
(IQR 42–53, range 35–69)
45 years
(IQR 38–46, range 38–48)
51 years
(IQR 46–56, range 20–72)
53 years
(IQR 50–61, range 35–62) 0.076
Age at surgery since 2016,
median (IQR, range)
51 years
(IQR 47–56, range 42–65)
49 years
(IQR 47–51, range 46–56) 60 years
∫ 51 years
(IQR 43–52, range 42–61)
64 years
(IQR 62–65, range 62–65) 0.082
Surveillance visits prior to surgery,
median N (IQR) 3 (IQR 1–5) 4 (IQR 2–7) 2 (IQR 1–4) 3 (IQR 1–5) 2 (IQR 1–3) 0.002
Reasons for surgery 0.158
Risk-reducing surgery, N (% of total
per gene) 53 (71.6%) 10 (71.4%) 3 (37.5%) 34 (77.3%) 6 (75.0%)
Surgery after abnormal surveillance
visit, N
(% of total per gene)
13 (17.6%) 1 (7.1%) 2 (25.0%) 8 (18.2%) 2 (2.7%)
Other (% of total per gene) 3 (4.1%) 2 (14.2%) 1 (12.5%) 0 0
Unknown (% per gene) 5 (6.8%) 1 (7.1%) 2 (25.0%) 2 (4.5%) 0
Abnormalities † identified upon
pathological assessment, N
(% of total per gene)
3 (4.1%) 0 0 3 † (4.1%) 0
‡ Surgery due to identification of a gynecological malignancy is herein not included. † Hyperplasia (n = 2) and EC (n = 1) were identified in pathology specimens of MSH6 carriers with surgery. ∆ Ovariectomy
with or without fallopian tubes
∫
N = 1, therefore no interquartile range (IQR) or range.
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3.2.4. Abnormalities Indicative for (pre)Malignancy
Other abnormal tests were found in 19 carriers upon second or higher surveillance
visits: an increased CA125 value (n = 6), a thickened endometrium (n = 10), and hyperplasia
(n = 3, Table 2). The latter three carriers opted for gynecological surgery, but pathological
assessment did not result in identification of an EC. Additionally, endometrial sampling
was suggestive for premalignancy for an MLH1 carrier. Subsequent hysterectomy with
bilateral salpingo-oophorectomy resulted in identification of an EC (Table 3).
3.3. Risk-Reducing Surgery
Of all 164 carriers enrolled in gynecological surveillance, 73 (45.5%) underwent gyneco-
logical surgery (Table 4). In 53 carriers, surgery was performed as a risk-reducing measure,
whereas in 13 carriers, surgery was performed due to suspicion of (pre)malignancies. In
three cases, surgery was performed for other gynecological problems, like uterine myomas,
and for the remaining five cases, the reason for gynecological surgery was unknown. The
procedures performed were hysterectomy with bilateral salpingo-oophorectomy (n = 58),
hysterectomy (n = 11), and ovariectomy with or without removal of the fallopian tubes
(n = 4, Table 4). Reasons for the performance of ovariectomy without simultaneous hys-
terectomy, for example as risk-reducing surgery or other reasons, could not be retrieved
for these carriers. Pathological assessment revealed one EC in a 58-year old MSH6 carrier,
without gynecological complaints (Tables 3 and 4).
In general, surgery was performed at a median age of 51 years (IQR 45–55 years before
2016 and IQR 47–56 since 2016), with no significant age differences between carrier groups.
In general, three surveillance visits (IQR 1–5) preceded this surgery. MSH6 carriers opted
significantly more for gynecological surgery compared to the other MMR gene carrier
groups (n = 44, 53.7% of all MSH6 carriers enrolled, p = 0.003; Table 4).
4. Discussion
In the current study, we assessed gynecological tumors, surgery, and surveillance
outcomes in 505 LS carriers. Of these carriers, 104 had a gynecological malignancy prior to
their genetic diagnosis of LS. Outcomes of gynecological management were assessed in
164 LS carriers, eligible for gynecological surveillance and/or risk-reducing surgery. More
than 80% of surveillance visits were performed within the advised timeframe. Endometrial
sampling revealed endometrial hyperplasia in eight carriers, of whom three symptomatic
carriers. Additionally, endometrial sampling revealed an EC in two asymptomatic carriers.
Additionally, four ECs and one OC were found in carriers with gynecological complaints
during the study period. Almost half of the carriers under surveillance (45.5%), and
particularly MSH6 carriers, opted for risk-reducing surgery, at a median age of 51 years.
Pathological assessment of the uterus after risk-reducing surgery revealed one EC in an
asymptomatic MSH6 carrier. To our knowledge, this is the first study with a relatively large
cohort of especially MSH6 carriers examining the outcomes of gynecological management
guidelines in the Netherlands.
4.1. Surveillance
In the Netherlands, there is a relatively high prevalence of MSH6 pathogenic variants.
Some Dutch studies particularly indicated a high EC risk for these carriers [30,31]. This has
probably influenced risk counseling in female MSH6 carriers. A more stringent risk-reducing
surgery advice for these carriers could therefore partially explain the significant longer
median follow-up of MLH1 and MSH2 carriers, compared to MSH6 and PMS2 carriers in
our cohort. Additionally, genetic testing for MSH2 and MLH1 was available earlier.
Although efficacy of gynecological screening is being questioned by some [23], two
studies performed in the Netherlands did show that premalignant lesions and early EC
could be identified in LS carriers [32,33]. In our cohort, transvaginal ultrasound was
performed in about three quarters of surveillance visits. A recent study showed that its
application generally causes little discomfort in post-menopausal women [34]. Addition of
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endometrial sampling was found to be more efficient in EC diagnosis than transvaginal
ultrasound alone [18,33,35,36]. In our cohort, endometrial sampling was performed in
about one third of visits. This could potentially be attributed to its painful application [37].
It can be hypothesized that, particularly in an asymptomatic postmenopausal woman
with a thin endometrial thickness, the posttest chance of finding an EC is so small that the
patient and her physician decide that sampling does not weigh in. CA125 measurements,
useful in identification of OC and also advised by national Dutch surveillance guidelines,
were performed in 40% of surveillance visits. Some hospitals may only perform CA125
measurements at the first surveillance visit and not routinely at every subsequent visit.
However, as CA125 measurements were performed at least once in slightly more than 60%
of carriers, this might need attention. Reason for the variation in application of transvaginal
ultrasound, endometrial sampling, and CA125 measurements could potentially be found
in the fact that surveillance takes place in different hospitals. A recent study by Ryan et al.
showed regional variation in gynecological surveillance visits. Additionally, about one-
third of the gynecological oncologists were unfamiliar with gynecological surveillance
guidelines [38].
4.2. Tumors
Among the studied carriers eligible for surveillance, hyperplasia was identified in
eight carriers, of whom three had gynecological complaints. Four ECs and one OC were
found in carriers having gynecological complaints. Endometrial biopsy revealed two ECs
in asymptomatic carriers. One of these carriers had endometrial sampling performed in her
visit prior to the identification of the tumor, without clues for premalignancy. One EC was
diagnosed upon pathological assessment after risk-reducing surgery, in an asymptomatic
carrier. In our study, three carriers with endometrial hyperplasia and more than half of
carriers with EC were symptomatic. On the one hand, these findings question whether,
and if so, to what extent, female LS carriers may benefit from gynecological surveillance
programs. On the other hand, these findings also highlight the importance of informing
LS carriers about gynecological complaints, indicative for an underlying (pre)malignancy.
Furthermore, these findings stress the importance of gynecological assessment in the case
of gynecological complaints, regardless of age, as blood loss in a 37-year old carrier led to
the identification of an EC.
4.3. Difference in Risk-Reducing Surgery
Risk-reducing surgery, usually hysterectomy combined with bilateral salpingo-oophorectomy,
was shown to be both effective and cost-effective in decreasing the gynecological cancer
risk [26,39]. In our cohort, about half of patients opted for risk-reducing surgery, of
which more than three-quarters chose for hysterectomy combined with bilateral salpingo-
oophorectomy. MSH6 carriers chose significantly more often for risk-reducing surgery. This
was in contrast to MSH2 carriers (32.0% vs. 53.7% in MSH6 carriers), whereas these carriers
were recently predicted as having the highest EC risk of all carrier groups [10]. Notably, in
18 MSH2 carriers with follow-up data available, two ECs and one endometrial hyperplasia
were diagnosed in our study, representing the highest amount of (pre)malignancies of all
carrier groups. The fact that MSH2 carriers chose less often for risk-reducing measures,
could potentially be due to a phenomenon also noticed by Sun et al.: in this study, female
LS carriers with a family history of cancer chose surprisingly less often for risk-reducing
measures than their counterparts without a family history of cancer [40]. The authors
attribute this to possible favorable experiences of relatives with endometrial cancer, since
symptoms allow early diagnosis of the cancer in a curable stage. In case MSH2 carriers in
our study did opt for risk-reducing surgery, they were younger.
4.4. Relevance
Although it has not yet been proven that gynecological surveillance causes identifica-
tion of a gynecological tumor in an earlier stage, guidelines currently advise LS carriers
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regular examination [15]. Surveillance is advised in view of the high risk of developing
gynecological tumors, which can be as high as 48% [10]. Additionally, EC is often the
presenting tumor in female LS carriers [41]. Assessment of gynecological management
strategies is thus of utmost importance and functions as a first step in the quest for more tai-
lored surveillance guidelines. Several factors hamper the development of these guidelines:
first, in contrast to CRC, little is known about the precursor lesions preceding EC or OC,
especially in LS carriers. Some studies, however, showed that mismatch repair deficiency
already occurs early in the carcinogenesis pathway [22,42]. Second, identification of pre-
cursor lesions in practice is hindered in premenopausal women, as endometrial sampling
was shown to have lower specificity and sensitivity in these women [43]. Third, it is not
certain if surveillance-detected cancers differ from incidence cancers: EC often presents
with vaginal bleeding, particularly in postmenopausal women. Consequently, ECs are
mostly detected in early stage with a favorable outcome. Therefore, some advocate that
gynecological surveillance in LS carriers should mainly take place based on complaints. A
previous study, that assessed OCs in LS carriers, found OCs in a predominantly early stage,
but noticed that annual gynecological surveillance was not causative for identification in
the early stage [44]. In the current study, however, one OC was identified in FIGO stage IV,
despite gynecological complaints.
4.5. Strengths and Limitations
Strengths of our study were the relatively large cohort of LS carriers, which made it
possible to mutually compare the four LS carrier groups. Second, the acquisition of extensive
data among others risk-reducing surgery and assays performed during these visits, provided
us with an accurate overview of gynecological management in these carriers.
Our study had several limitations. First, due to the retrospective nature of this study,
we were hampered by missing data. Therefore, for some carriers, some surveillance
visits might not have been included in our analysis and non-surveillance visits might be
misinterpreted. Bias could be introduced because we had no information on the women
who did not grant informed consent to retrieve their gynecological management data and
women who did not have screening after LS diagnosis. To what extent these carriers were
enrolled in a gynecological management program remained unknown. As a consequence,
development of EC in both groups could not be compared. Second, although our cohort
included a relatively large number of LS carriers when compared to previous literature,
larger groups are needed to draw definite conclusions about surveillance efficacy. Our
cohort consists of patients included from 1993 to 2020. During this time span, several
changes can be noted: the recognition of new mutations, changes in cancer incidence
data, and screening protocols having evolved over time. This, however, is an ongoing
process: today’s recommendations will be adjusted in the future. To accurately assess
gynecological surveillance efficacy of currently used guidelines, we plan to carry out a
nationwide, prospective study.
5. Conclusions
In conclusion, we assessed gynecological tumors and gynecological management in
505 LS carriers diagnosed in our center. Of 164 LS carriers, data on gynecological surveil-
lance and/or risk-reducing surgery were available and evaluated. Risk-reducing surgery
was eventually performed in nearly half of these 164 LS carriers, especially MSH6 carriers.
Most of the surveillance visits were performed in time. Three out of eight carriers with
endometrial hyperplasia had gynecological complaints. Four of seven EC patients and
the one patient with OC had gynecological complaints, whereas three ECs were found in
asymptomatic women. All ECs were diagnosed in FIGO I. This questions whether, and if
so, to what extent, female LS carriers may benefit from current gynecological surveillance
programs. Larger, prospective studies are warranted to determine the efficacy and com-
pliance of gynecological surveillance strategies in LS carriers. Additionally, alternatives
should be assessed: for example, gynecological surveillance in which female carriers only
Cancers 2021, 13, 459 14 of 16
reach out when having gynecological complaints. As a consequence, uniform surveillance
strategies can be developed and implemented.
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